Tectonic Therapeutic Inc (NASDAQ: TECX)’s stock price has plunge by -6.60relation to previous closing price of 25.16. Nevertheless, the company has seen a 3.71% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-17 that WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic’s lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.
Is It Worth Investing in Tectonic Therapeutic Inc (NASDAQ: TECX) Right Now?
The 36-month beta value for TECX is also noteworthy at 1.50. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TECX is 10.59M, and at present, short sellers hold a 11.97% of that float. The average trading volume of TECX on June 12, 2025 was 206.77K shares.
TECX’s Market Performance
The stock of Tectonic Therapeutic Inc (TECX) has seen a 3.71% increase in the past week, with a 13.47% rise in the past month, and a -4.55% fall in the past quarter. The volatility ratio for the week is 5.53%, and the volatility levels for the past 30 days are at 4.66% for TECX. The simple moving average for the past 20 days is 4.31% for TECX’s stock, with a -24.32% simple moving average for the past 200 days.
Analysts’ Opinion of TECX
Many brokerage firms have already submitted their reports for TECX stocks, with Raymond James repeating the rating for TECX by listing it as a “Outperform.” The predicted price for TECX in the upcoming period, according to Raymond James is $76 based on the research report published on June 11, 2025 of the current year 2025.
Mizuho, on the other hand, stated in their research note that they expect to see TECX reach a price target of $51. The rating they have provided for TECX stocks is “Outperform” according to the report published on April 21st, 2025.
Raymond James gave a rating of “Outperform” to TECX, setting the target price at $65 in the report published on November 20th of the previous year.
TECX Trading at 16.12% from the 50-Day Moving Average
After a stumble in the market that brought TECX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.52% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECX starting from SPRINGER TIMOTHY A, who purchase 53,706 shares at the price of $16.31 back on Apr 11 ’25. After this action, SPRINGER TIMOTHY A now owns 1,503,358 shares of Tectonic Therapeutic Inc, valued at $875,945 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Tectonic Therapeutic Inc, purchase 45,858 shares at $16.73 during a trade that took place back on Apr 10 ’25, which means that SPRINGER TIMOTHY A is holding 1,449,652 shares at $767,204 based on the most recent closing price.
Stock Fundamentals for TECX
The total capital return value is set at -0.21. Equity return is now at value -30.10, with -28.82 for asset returns.
Based on Tectonic Therapeutic Inc (TECX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -24.54. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -666.81.
Currently, EBITDA for the company is -56.23 million with net debt to EBITDA at 5.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.92.
Conclusion
In summary, Tectonic Therapeutic Inc (TECX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
